Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ventripoint to Sponsor the Annual Meeting of the British Congenital Cardiac Association



Ventripoint Diagnostics Ltd.

Toronto, Ontario – TheNewswire – November 4, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be a gold sponsor for the 2022 Annual Scientific Meeting of the British Congenital Cardiac Association (BCCA). Dr. Gregory Skinner, a Clinical Advisor to the Company, will be giving a presentation that will highlight the use of the VMS+3.0 in retrieving volumetric and functional data for managing cardiac heart disease patients.

The meeting will take place on Monday 7th and Tuesday 8th of November 2022 at the International Conference Centre in Birmingham, UK. The BCCA meeting attracts over 400 delegates from across the UK and worldwide with a focus in adult and paediatric congenital cardiology. The attendees will be members of various cardiac associations and health care professionals, which each year creates a valuable networking experience.

Dr. Skinner’s presentation will take place on November 8th, 2022 and is entitled: “Accurate, Reproducible Volumetric and Functional Data for Managing Congenital Heart Disease Using VMS From Ventripoint”. The presentation will focus on the unique abilities of the VMS+3.0 in the management of congenital cardiac patients through case studies and real-life examples.

Exhibiting at the BCCA meeting continues Ventripoint’s ongoing efforts to make the cardiology community aware of the benefits of the VMS+3.0 and allow them to have a hands-on experience of the ease of use of the system in the exhibition booth and then schedule an on-site demonstration at their clinic.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Copyright (c) 2022 TheNewswire - All rights reserved.